US20060160752A1 - Promoter for the production of hyaluronic acid containing ginsenoside compound k - Google Patents

Promoter for the production of hyaluronic acid containing ginsenoside compound k Download PDF

Info

Publication number
US20060160752A1
US20060160752A1 US10/539,011 US53901105A US2006160752A1 US 20060160752 A1 US20060160752 A1 US 20060160752A1 US 53901105 A US53901105 A US 53901105A US 2006160752 A1 US2006160752 A1 US 2006160752A1
Authority
US
United States
Prior art keywords
hyaluronic acid
compound
skin
production
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/539,011
Other languages
English (en)
Inventor
Su-Jong Kim
Byung-Young Kang
Si-Young Cho
Hui-Kyoung Chang
Dae-Seok Sung
Myeong-Hoon Yeom
Kwang-Sik Woe
Duck-Hee Kim
Han-Kon Kim
Young-Chul Sim
Hak-Hee Kang
Yong-Sung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Assigned to AMOREPACIFIC CORPORATION reassignment AMOREPACIFIC CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIM, YOUNG-CHUL, WOE, KWANG-SIK, KIM, DUCK-HEE, CHO, SI-YOUNG, KANG, BYUNG-YOUNG, KANG, HAK-HEE, KIM, HAN-KON, CHANG, HUI-KYOUNG, KIM, SU-JONG, LEE, YONG-SUNG, SUNG, DAE-SEOK, YEOM, MYEONG-HOON
Publication of US20060160752A1 publication Critical patent/US20060160752A1/en
Priority to US12/184,622 priority Critical patent/US8173607B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a promoter containing ginsenoside compound K for the production of hyaluronic acid. More particularly, the present invention provides a new efficacy of 20-O- ⁇ -D-glucopyranosyl-20(S)-protopanaxadiol (called “compound K”), a chief metabolite of ginseng saponin, to increase the expression of the hyaluronic acid synthase (HAS) gene in human cells and thereby to promote the production of hyaluronic acid (HA), and provides a promoter containing compound K for the production of hyaluronic acid.
  • compound K 20-O- ⁇ -D-glucopyranosyl-20(S)-protopanaxadiol
  • HAS hyaluronic acid synthase
  • Hyaluronic acid is a nonsulfated glycosaminoglycan, linear polysaccharide with a very large molecular weight of 200,000 to 400,000 composed of repeating glucuronic acid and N-acetylglucosamine residues.
  • Hyaluronic acid is a major structural component of the extracellular matrix and involved in water retention, maintenance of the extracellular space and storage and diffusion of cell growth factors and nutrients, as well as in cell proliferation and differentiation, and migration.
  • hyaluronic acid exists in the skin, particularly in epidermal extracellular space and dermal connective tissue, and it is synthesized by keratinocyte and fibroblasts. Further, the concentration of hyaluronic acid in human skin decreases with aging, which causes the skin to lose its elasticity and to decrease water retention ( Biochem Biophys Acta 279, 265-275, Carbohydr Res 159, 127-136, Int J Dermatol 33, 119-122).
  • the human joint capsule is composed of the outer fibrous layer and the inner synovial membrane, in which synovial fluid containing hyaluronic acid and glycoprotein, functions as a joint lubricant. It has however been reported that in osteoarthritis (degenerative arthritis), the production of hyaluronic acid decreases and destruction by proteolytic enzymes is accelerated, so diminishing the concentration of hyaluronic acid in a joint. Therefore as the concentration of hyaluronic acid in a joint decreases, the joint cannot absorb or disperse shocks, so accelerating cartilage damage. Hence, hyaluronate injection was approved by the FDA in 1997 as a device for the relief of pain from osteoarthritis and has been applied thereto. However, in the end, it may be more effective to increase the biosynthesis of hyaluronic acid.
  • estradiol and its derivatives applied on the skin might increase the biosynthesis of hyaluronic acid ( Steroids 16,1-3, J Invest Derinatol 87, 668-673, Skin Pharmacol Appl Skin Physiol 15, 175-183).
  • the detailed mechanism for the metabolism of hyaluronic acid has not yet been fully elucidated. It has been merely known that hyaluronic acid is synthesized at the inner surface of the plasma membrane by hyaluronic acid synthase and is extruded through the membrane into the extracellular space simultaneously with the ongoing synthesis ( J. Biol. Chem. 272, 13997-14000).
  • HAS1 human epidermal growth factor
  • HAS2 epidermal growth factor
  • hyaluronic acid can be promoted by treatment with compound K, resulting in increasing the concentration of hyaluronic acid in the human body.
  • compound K can be applied to various purposes utilizing the efficacy of hyaluronic acid such as skin-care uses for improvement of skin elasticity and prevention of skin drying or skin aging and pharmaceutical uses for treatment or prevention of osteoarthritis. Based on this finding, the present invention has been completed.
  • an object of the present invention is to provide a new use of compound K to increase the expression of the hyaluronic acid synthase gene and thereby to promote the production of hyaluronic acid.
  • Another object of the present invention is to provide a promoter for the production of hyaluronic acid containing compound K as an effective ingredient.
  • a further object of the present invention is to provide the possibility of compound K being applied to various purposes utilizing the efficacy of hyaluronic acid such as skin-care uses for improvement of skin elasticity and prevention of skin drying or skin aging and pharmaceutical uses for treatment or prevention of osteoarthritis.
  • the present invention provides a new efficacy of compound K, which already has been known to have efficacies such as an immunity-increasing effect, a tumor angiogenesis-suppressing effect and a cancerous cell permeation-inhibiting effect. That is to say, the invention provides a new efficacy of compound K to increase the expression of the hyaluronic acid synthase gene and thereby to promote the production of hyaluronic acid.
  • Compound K that is, 20-O- ⁇ -D-glucopyranosyl-20(S)-protopanaxadiol represented by the following formula 1, is a chief metabolite of ginseng saponin decomposed by human intestinal bacteria (Hasegawa, H., Sung, J. H., Matsumiya. S., Uchiyama. M.,(1996) Planta Medica 62, 453-457).
  • Ginsenosides and theirs derivatives derived from ginseng have the constitutions that sugar such as glucose, rhamnose, arabinose, xylose or the like is linked via ether bond to protopanaxadiol or protopanaxatriol, which are triterpenes of the dammarane series. So far, a total of a 29 types of gensenosides have been isolated from ginseng (KOREA INSAM). Shibata, in 1964, named the components of ginseng saponin as “ginsenoside”, which refers to glycoside contained in ginseng.
  • Ginsenosides are classified into ginsenoside-Ro, which is a family of oleanane saponin, and ginsenoside-Ra, -Rb1, -Rb2, -Rc, -Rd, -Re, -Rf, -Rg1, -Rg2, -Rg3 and -Rh, according to the order of movement in separating from TLC (thin-layer chromatography). Ginseng saponins have been known to exhibit different pharmacological efficacies depending on their type, number or the position of sugar bonded to aglycon.
  • compound K i.e. 20-O- ⁇ -D-glucopyranosyl-20(S)-protopanaxadiol
  • compound K is composed of one sugar (glucose) bonded to protopanaxadiol and has been known to exhibit pharmacological efficacy in suppressing cancerous cell proliferation, suppressing tumor cell proliferation and enforcing anticancer activity of anticancer agents.
  • extensive studies on saponin metabolites revealed that the pharmacological efficacy of ginseng saponin is due to the metabolites decomposed by human intestinal bacteria, not to the saponin itself ( Chem Pharm Bull 38(10) 2859-2861, Bio. Pharm. Bull 25(6) 743-747).
  • HAS2 gene expression increased in compound K-treated human epidermal and dermal cell lines i.e. keratinocyte cell line HaCaT and fibroblast cell line HDF. That is, treatment with compound K for 24 hours induced 3-times and 2.5-times increases in HAS2 gene expression in the cultured HaCaT and HDF cells respectively, in comparison with no treatment. Furthermore, HAS2 gene expression increased about 3-times and about 5-times during 24 hours and 48 hours incubations of HaCaT cells with treatment of 1 ⁇ M compound K, respectively. These results show that compound K has HAS2 gene expression-promoting efficacy in human cell. At the same time, it was confirmed that the concentration of hyaluronic acid in the human cell culture was increased by treatment of compound K.
  • the present inventors confirmed that the production of hyaluronic acid increased in the compound K-treated hairless mouse skin.
  • compound K was introduced to a patch and applied onto the back skin of a hairless mouse, the production of hyaluronic acid increased about 3-times in the epidennis and dermis.
  • Compound K employed in the present invention may be natural compound K or synthetic compound K obtained by the conventional method, but not limited thereto.
  • Compound K may be obtained by dissolving purified saponin of ginseng in aqueous solvent such as distilled water or buffer solution, or in a mixture of the aqueous solvent and organic solvent, and then reacting with at least one of naringinase separated from Penicillium and pectinase separated from Aspergillus, but not limited thereto.
  • compound K can increase HAS2 gene expression and promote the production of hyaluronic acid. Accordingly, compound K can be incorporated, as an effective component, into skin-care topical compositions utilizing the efficacy of hyaluronic acid. For example, it can be added into skin-care topical compositions for improvement of skin elasticity and prevention of skin drying or skin aging. Further, it can be added into medicaments for treatment or prevention of diseases, such as osteoarthritis, by administration of hyaluronic acid. However, it may not be limited thereto.
  • FIG. 1 is a result of quantitative RT-PCR for HAS2 gene, in order to identify HAS2 mRNA expression in keratinocyte cell line HaCaT ( FIG. 1 a ) and fibroblast cell line HDF ( FIG. 1 b ) after treatment with various concentrations of compound K.
  • FIG. 2 is a result of quantitative RT-PCR for HAS1, HAS2 and HAS3 genes, in order to identify HAS mRNA expression in HaCaT cells after treatment with compound K for various time periods.
  • FIG. 3 shows the effect of compound K on the distribution of hyaluronic acid in the cultured HaCaT and HDF cells. After treatment with 1 ⁇ M of compound K, the increased production of hyaluronic acid was confirmed by the immunocytochemical method and then the result was quantitated.
  • FIG. 4 shows the increased production of hyaluronic acid in the compound K-treated back skin of the hairless mouse, confirmed by immunohistochemical staining.
  • FIG. 5 shows morphological changes in human skin by treatment with the compound K-containing topical composition.
  • Spontaneously immortalized human keratinocyte cell line, HaCaT was provided by Dr. N.E. Fusenig (Deutsches Krebsgeberstechnik(DKFZ), Heidelberg, Germany) and human diploid fibroblast cell line, HDF, was provided by Dr. S.C. Park (Seoul National University, Seoul, Korea).
  • the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), sodium bicarbonate (3.6g/l) and antibiotics of streptomycin (100 ⁇ g/ml) and penicillin (100 U/ml) (Life Technologies, Inc.) at 37° C. in a humidified atmosphere containing 5% CO 2 and 95% air.
  • DMEM Dulbecco's modified Eagle's medium
  • HyClone fetal bovine serum
  • sodium bicarbonate 3.6g/l
  • antibiotics of streptomycin 100 ⁇ g/ml
  • penicillin 100 U/ml
  • the cells were seeded into a tissue culture flask at 1 ⁇ 10 5 cells per 75 cm 2 and cultured in the medium with 10% fetal bovine serum for 24 hours. Subsequently, the cells were cultured in the serum-free medium for another 24 hours and then in fresh serum-free medium supplemented with 1 to 5 ⁇ M of compound K for 3, 6, 12, 24 or 48 hours. As a control, the cells were cultured in the medium supplemented with 0.01% vehicle (dimethylsulfoxide, DMSO). In the control, no effect of DMSO on cell growth and differentiation was observed.
  • vehicle dimethylsulfoxide
  • RNA concentration was measured by spectrophotometry and RNA integrity was checked by agarose gel electrophoresis.
  • 4ug of total RNA was reverse transcribed in 25 l of reaction mixture containing 2.5 U/ ⁇ l Superscript II reverse transcriptase (Invitrogen, Carlsbad, Calif.), 1 U/ ⁇ l RNase inhibitor, 5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH8.3), 2.5 ⁇ M oligo(dT) primers and 1 mM dNTPs.
  • the reaction mixture was gently incubated at 42° C. for 60 min, to be subjected to reverse transcription. Then, the reverse transcriptase was inactivated by heating at 85° C. for 5 min.
  • PCR was performed using Perkin-Elmer Cycler 9600(Perkin-Elmer Applied Biosystems, Foster, Calif.) in 50 ⁇ l of reaction mixture containing 0.04U/ ⁇ l AmpliTaq DNA polymerase (Perkin Elmer, Shelton, Connecticut), 50 mM Tris (pH8.3), 0.25 ⁇ g/ml BSA, 3 mM MgCl 2 , 0.25 mM dNTPs and 0.25 ⁇ M sense or antisense PCR primers (Table 1) under a PCR thermal profile consisting of denaturation at 95° C.
  • GAPDH is a criterion for standardization of the amplified products.
  • FIG. 1 is a result of quantitative RT-PCR for HAS2 gene, in order to identify HAS mRNA expression in keratinocyte cell line HaCaT ( FIG. 1 a ) and fibroblast cell line HDF ( FIG. 1 b ) after treatment with various concentrations of compound K, and shows the effect of the compound K on HAS2 mRNA level.
  • HAS2 mRNA was detected in a small amount in the control, but increased 3-times and 2.5-times in compound K-treated HaCaT cells and HDF cells, respectively.
  • FIG. 2 shows the effect of compound K on HAS1, HAS2 and HAS3 transcription in the HaCaT cells.
  • HaCaT cells were cultured for 24 or 48 hours in the medium with 0 or 1 ⁇ M compound K added thereto, then total RNA was isolated therefrom. Total RNA was reverse transcribed and amplified for 30 PCR cycles.
  • HAS2 transcription increased about 3-times and about 5-times during 24 hr and 48 hours incubation of HaCaT cells treated with compound K, respectively.
  • compound K did not influence the HAS1 and HAS3 mRNA levels detected in small amount.
  • HaCaT and HDF cells were washed with PBS then fixed in a fixative with 2% paraformaldehyde(v/v) and 0.5% glutaraldehyde(v/v) at room temperature for 20 min. After fixation, the cells were washed three times for 2 min each with 0.1 M sodium phosphate buffer (pH7.4), then blocked in 1% bovine serum albumin (w/v) containing 0.1% Triton X-100 (v/v) in the same buffer at room temperature for 30 min. Hyaluronan staining was carried out with a specific probe of biotinylated hyaluronan binding protein (bHABP) (Seikagaku, Tokyo, Japan).
  • bHABP biotinylated hyaluronan binding protein
  • the bHABP probe diluted to 5 ⁇ g/ml in 3% bovine serum albumin (w/v), was added to the fixed cells and was incubated overnight at 4° C. Afterwashing, avidin-fluorescein isothocyanate (FITC) was added. Images were analyzed with fluorescent microscope and are shown in FIG. 3 .
  • FIG. 3 shows the effect of compound K on the distribution of hyaluronic acid in the cultured HaCaT and HDF cells.
  • HaCaT cells FIG. 3 a, FIG. 3 b
  • HDF cells FIG. 3 c, FIG. 3 d
  • FIG. 3 a, FIG. 3 c were cultured in the presence of 1 ⁇ M compound K ( FIG. 3 b, FIG. 3 d ) or in the absence of compound K ( FIG. 3 a, FIG. 3 c ).
  • Hyaluronan staining was carried out with bHABP(Seikagaku). Each skin sample was fixed with 2% formaldehyde and 0.5% glutaraldehyde in PBS, embedded and sectioned. After deparaffinization, sections were incubated in 0.3% H 2 O 2 in methanol at room temperature for 30 min, washed with PBS, then blocked in 1% bovine serum albumin. Subsequently the sections were incubated in 5 mg/ml bHABP in PBS at 4° C. then, after washing, incubated with streptoavidin-peroxidase, diluted to 1/300 in PBS at room temperature, for 30 min.
  • each slide was reacted with 3,3′-diaminobenzidine tetrahydrochloride(DAB) at room temperature for 5 min. After washing with distilled water, staining was carried out with Mayer's hematoxylin.
  • DAB 3,3′-diaminobenzidine tetrahydrochloride
  • FIG. 4 shows hyaluronic acid widely deposited in the epidermis and dermis. It shows that hyaluronic acid significantly increased in compound K-treated hairless mouse skin. As shown in FIG. 4 a and FIG. 4 b, the amount of hyaluronic acid increased predominantly in the extracellular papillary dermis and in the viable epidermis of the compound K-treated murine skin.
  • FIG. 4 c is a result of quantitative image analysis, showing that the amount of HA increased 3-folds in epidermis and dermis of the compound K-treated murine skin, respectively, as compared with the untreated skin. (p ⁇ 0.05).
  • Skin-care efficacies such as facial wrinkle, fine wrinkle, hydration, elasticity, smoothness, roughness and brightness were evaluated by the volunteers and skin expert inspectors. Difference before and after using topical samples and improvement were detennined by photometry evaluation with Camscope®(model DCS-105) and by image analysis of silicon replica with Skin-Visiometer SV 600(Courage & Khazaka, Germany).
  • FIG. 5 shows a result of evaluation with global photodamage score conducted by skin expert inspectors.
  • compound K induced statistically significant decrease in facial wrinkle and fine wrinkle ( FIG. 5 a ).
  • 76% of volunteers after 8 weeks of use and 92% of volunteers after 12 weeks of use gave positive and affirmative estimate ( FIG. 5 b )
  • compound K a chief metabolite of ginseng saponin, can increase expression of gene coding hyaluronic acid synthase 2 and thereby activate the production of hyaluronic acid in a living body. Therefore, compound K can be used for effective prevention of skin elasticity reduction, water retention reduction and skin aging. Further, it can be effectively used for prevention and treatment of osteoarthritis, utilizing hyaluronic acid for remedial value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
US10/539,011 2002-12-26 2003-09-16 Promoter for the production of hyaluronic acid containing ginsenoside compound k Abandoned US20060160752A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/184,622 US8173607B2 (en) 2002-12-26 2008-08-01 Promoter for the production of hyaluronic acid containing ginsenoside compound K

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2002-0084036A KR100485326B1 (ko) 2002-12-26 2002-12-26 진세노사이드 화합물 ｋ로 이루어진 히알루론산 생성촉진제
KR10-2002-0084036 2002-12-26
PCT/KR2003/001889 WO2004058796A1 (en) 2002-12-26 2003-09-16 Promoter for the production of hyaluronic acid containing ginsenoside compound k

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/184,622 Continuation US8173607B2 (en) 2002-12-26 2008-08-01 Promoter for the production of hyaluronic acid containing ginsenoside compound K

Publications (1)

Publication Number Publication Date
US20060160752A1 true US20060160752A1 (en) 2006-07-20

Family

ID=36684731

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/539,011 Abandoned US20060160752A1 (en) 2002-12-26 2003-09-16 Promoter for the production of hyaluronic acid containing ginsenoside compound k
US12/184,622 Expired - Fee Related US8173607B2 (en) 2002-12-26 2008-08-01 Promoter for the production of hyaluronic acid containing ginsenoside compound K

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/184,622 Expired - Fee Related US8173607B2 (en) 2002-12-26 2008-08-01 Promoter for the production of hyaluronic acid containing ginsenoside compound K

Country Status (7)

Country Link
US (2) US20060160752A1 (zh)
EP (1) EP1575982B1 (zh)
JP (1) JP4580242B2 (zh)
KR (1) KR100485326B1 (zh)
CN (1) CN100376595C (zh)
AU (1) AU2003261657A1 (zh)
WO (1) WO2004058796A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281049A1 (en) * 2006-09-19 2009-11-12 Quanhai Liu New use of ginsenoside compound-k in manufacturing medicaments
WO2010134650A1 (en) 2009-05-19 2010-11-25 Il Hwa Co., Ltd. Methods for preparing a fermented ginseng concentrate or powder
US20120150001A1 (en) * 2010-11-04 2012-06-14 Compact Imaging Hyaluronic acid based glucose monitoring

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051091A (ja) * 2005-08-18 2007-03-01 Shiseido Co Ltd ヒアルロン酸産生促進剤
WO2010150612A1 (ja) 2009-06-22 2010-12-29 株式会社Ｊ－オイルミルズ ヒアルロン酸産生促進剤及びメラニン生成抑制剤
KR101427572B1 (ko) * 2009-11-25 2014-08-08 (주)아모레퍼시픽 진세노사이드 Ｒｅ 및 진세노사이드 화합물 Ｋ를 함유하는 히알루론산 생성 촉진용 피부 외용제 조성물
JP6175216B2 (ja) * 2010-03-08 2017-08-02 丸善製薬株式会社 関節炎の予防・治療剤
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
WO2012173452A1 (ko) * 2011-06-16 2012-12-20 한국생명공학연구원 진세노사이드 컴파운드 ｋ 또는 이의 유도체로 된 항균제
FR3020570B1 (fr) * 2014-04-30 2017-07-21 Pierre Fabre Dermo-Cosmetique Association d'un acide hyaluronique et d'un polysaccharide sulfate
KR102029040B1 (ko) 2015-09-30 2019-10-07 (주)아모레퍼시픽 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물
CN106632570B (zh) 2016-09-19 2018-07-17 李晓辉 二醇型人参皂苷衍生物及其制备方法和应用
EP3562470A1 (en) 2016-12-29 2019-11-06 Nestlé Skin Health SA Composition comprising a crosslinked hyaluronic acid (ha) in combination with a low-molecular ha and/or an agent stimulating endogenous ha synthesis
EP3562469A1 (en) 2016-12-29 2019-11-06 Nestlé Skin Health SA Micro- or nanoparticular vesicles comprising crosslinked hyaluronic acid, compositions comprising the same and method for their use in skin care
KR20240018316A (ko) 2022-08-02 2024-02-13 원광대학교산학협력단 약물 전달 패치 및 그 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742987B1 (fr) * 1996-01-03 1998-04-03 Lvmh Rech Utilisation dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie, d'un extrait d'eriobotrya japonica pour stimuler la synthese des glycosaminoglycanes
KR0164266B1 (ko) * 1996-02-22 1999-01-15 오오니시 쿠니히로 인삼사포닌 장내세균 대사물 및 이를 유효성분으로하는 제암제제
FR2767057B1 (fr) * 1997-08-08 1999-10-29 Lvmh Rech Utilisation du ginsenoside rb1 comme agent destine a stimuler la synthese de l'elastine
US7235267B1 (en) * 1999-08-30 2007-06-26 Japan Science And Technology Corporation Brain cell or nerve cell-protecting agents comprising medicinal ginseng
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
KR100465977B1 (ko) 2002-01-05 2005-01-13 주식회사 태평양 나노유화기술에 의한 화합물 ｋ를 함유하는 미세 유화 입자 및 이를 사용한 피부 외용제 조성물
KR100835863B1 (ko) * 2002-04-08 2008-06-09 (주)아모레퍼시픽 나노유화기술에 의해 20-0-[α-Ｌ-아라비노피라노실(1-〉6)-β-Ｄ-글루코피라노실]-20(Ｓ)-프로토파낙사다이올을 함유하는 미세 유화 입자 및 이를 사용한 피부 외용제 조성물
KR100465976B1 (ko) 2002-01-05 2005-01-13 주식회사 태평양 나노유화기술에 의해 진세노사이드 ｆ1을 함유하는 미세 유화 입자 및 이를 사용한 피부 외용제 조성물
JP4549625B2 (ja) * 2002-01-05 2010-09-22 株式會社アモーレパシフィック 人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物
CN1240390C (zh) * 2002-01-30 2006-02-08 株式会社一和 生物转化人参组合物及其制备方法
KR100517899B1 (ko) * 2002-01-30 2005-09-30 주식회사 일화 생물전환 인삼 조성물 및 그 제조 방법
KR200360018Y1 (ko) 2004-06-01 2004-08-25 선우균 양면 실장형 세라믹 패키지
KR200360017Y1 (ko) 2004-06-01 2004-08-26 김길평 교량용 풍속감속벽
KR200365273Y1 (ko) 2004-07-31 2004-10-20 김소형 방한용 귀마개
KR200380429Y1 (ko) 2005-01-17 2005-03-31 박호선 마이크로폰의 노이즈 감소장치

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281049A1 (en) * 2006-09-19 2009-11-12 Quanhai Liu New use of ginsenoside compound-k in manufacturing medicaments
WO2010134650A1 (en) 2009-05-19 2010-11-25 Il Hwa Co., Ltd. Methods for preparing a fermented ginseng concentrate or powder
EP2432891A1 (en) * 2009-05-19 2012-03-28 Il Hwa Co., Ltd. Methods for preparing a fermented ginseng concentrate or powder
EP2432891A4 (en) * 2009-05-19 2015-04-22 Il Hwa Co Ltd PROCESSES FOR PREPARING A CONCENTRATE OR FERMENTED GINSENG POWDER
US20120150001A1 (en) * 2010-11-04 2012-06-14 Compact Imaging Hyaluronic acid based glucose monitoring

Also Published As

Publication number Publication date
JP2006515303A (ja) 2006-05-25
EP1575982B1 (en) 2012-06-13
US20090062217A1 (en) 2009-03-05
CN1717414A (zh) 2006-01-04
KR100485326B1 (ko) 2005-04-27
EP1575982A1 (en) 2005-09-21
KR20040057339A (ko) 2004-07-02
AU2003261657A1 (en) 2004-07-22
CN100376595C (zh) 2008-03-26
US8173607B2 (en) 2012-05-08
EP1575982A4 (en) 2010-05-26
JP4580242B2 (ja) 2010-11-10
WO2004058796A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
US8173607B2 (en) Promoter for the production of hyaluronic acid containing ginsenoside compound K
Kim et al. Compound K induces expression of hyaluronan synthase 2 gene in transformed human keratinocytes and increases hyaluronan in hairless mouse skin
EP1021161B1 (fr) Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie
JP2010500282A (ja) ケンペロールおよびケルセチンを含むヒアルロン酸の生成を促進するための組成物
KR20150070100A (ko) 화장적 또는 약학적 보습 성분
US20080045467A1 (en) Composition Containing Ginsenoside F1 Or Compound K For Skin External Application
US20050265944A1 (en) Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US5910490A (en) Use of oligosaccharides in the prevention and treatment of the aging of tissues
JP6850262B2 (ja) 皮膚の抗老化剤及び抗老化組成物
EP3721864A1 (en) Cosmetic composition for promoting skin exfoliation
Pineau et al. A new C-xylopyranoside derivative induces skin expression of glycosaminoglycans and heparan sulphate proteoglycans
JP2022527851A (ja) 炎症性皮膚疾患のためのデキストラン硫酸
Nuraeni et al. The spray of pegagan leaf extract as an antifungal of vulvovaginal candidiasis: A narrative review
KR101640735B1 (ko) 주름 개선용 조성물
WO2016080915A1 (en) Cosmetic use of heparan sulphate
CN110709088A (zh) 葡糖胺基葡聚糖产生促进剂及葡糖胺基葡聚糖产生促进用组合物
JPH09124497A (ja) Ｇｏｄタイプのエラジタンニンを有効成分とするヒアルロニダーゼ阻害剤並びにこれを配合した医薬品及び化粧品
EP1009378A1 (fr) Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
KR20140072419A (ko) 주름 개선용 조성물
WO2024100919A1 (ja) スフィンゴイド塩基を含む掻痒抑制に用いるための剤およびその用途
KR101640736B1 (ko) 주름 개선용 조성물
WO2022045261A1 (ja) Ｃｄ３９遺伝子の発現低下の抑制剤
Kim et al. Compound K Activates Hyaluronan Synthase 2 in transformed human Keratinocytes and Fibroblasts and Increases hyaluronan in hairless mouse skin
JP2024035284A (ja) ヒアルロン酸産生促進剤
EP4215200A1 (en) Autophagy activator

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMOREPACIFIC CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, SU-JONG;KANG, BYUNG-YOUNG;CHO, SI-YOUNG;AND OTHERS;REEL/FRAME:017796/0687;SIGNING DATES FROM 20051111 TO 20051121

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION